Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BenevolentAI Ltd (BenevolentAI) is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s pipeline products include BEN-8744 treats ulcerative colitis; BEN-28010 targets glioblastoma multiforme; BEN-34712 is for the treatment of Amyotrophic Lateral Sclerosis (ALS); Parkinson’s Disease treats novel target; Fibrosis targets fibrosis novel target. Benevolent AI’s platform enables scientists to design and develop new treatments for patients, using a large amount of extracted and deduced biomedical information. The company operates in the UK and the US. BenevolentAI is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
4-8 Maple Street, London, England, W1T5HD
Website
www.benevolent.com
Telephone
44 20 37819360
No of Employees
248
Industry
Pharmaceuticals and Healthcare
Revenue (2023)
$9.1M
BenevolentAI Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| BEN-8744: Ulcerative colitis |
| BEN-28010: Glioblastoma multiforme |
| BEN-34712: ALS |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Plans/Strategy | In February, the company announced its plans to merge with Osaka Holdings. |
| 2023 | Contracts/Agreements | In September, the company signed a collaboration with Merck to enable Merck to leverage the company’s powerful end-to-end AI platform. |
| 2022 | Contracts/Agreements | In October, the company and AstraZeneca partnered to integrates AstraZeneca’s data into its biomedical Knowledge Graph to rapidly normalise and contextualise a diverse range of external and internal data from numerous sources. |
Competitor Comparison
| Key Parameters | BenevolentAI Ltd | Cresset BioMolecular Discovery Ltd | 4D Pharma Plc | Acacia Pharma Group Ltd | Aria Pharmaceuticals Inc (Inactive) |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United States of America |
| City | London | Litlington | Leeds | Cheshire | Palo Alto |
| State/Province | England | Cambridgeshire | England | England | California |
| No. of Employees | 248 | 115 | 95 | - | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenneth Mulvany | Chairman | Executive Board | 2024 | - |
| Peter Allen | Deputy Chairman | Executive Board | 2024 | - |
| James Malone | Chief Technology Officer | Senior Management | 2024 | - |
| Anna Fullerton-Batten | Chief People Officer | Senior Management | 2022 | - |
| Anne Phelan | Chief Scientific Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer